Review anchor
Nuclear receptor subfamily 4 group A member 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Nuclear receptor subfamily 4 group A member 2
CHEMBL5002
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Nuclear receptor subfamily 4 group A member 2 as ChEMBL target CHEMBL5002, mapped to UniProt P43354. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5002
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P43354
Nuclear receptor subfamily 4 group A member 2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Nuclear receptor subfamily 4 group A member 2 matters
Nuclear receptor subfamily 4 group A member 2 is reviewed as Nuclear receptor subfamily 4 group A member 2 (UniProt P43354); the current evidence base includes 8 approved drugs, 333 compounds, and 254 assays, with lead potency reaching pChEMBL 9.1.
Protein context
Nuclear receptor subfamily 4 group A member 2
Nuclear receptor subfamily 4 group A member 2 Sequence length is 598 aa.
Review this target as Nuclear receptor subfamily 4 group A member 2, mapped to UniProt P43354. Sequence length is 598 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P43354
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 8 approved drugs, 333 compounds, and 254 assays for this target. The dominant activity type is EC50. CHEMBL399603 is the current potency anchor at pChEMBL 9.1.
Use CHEMBL399603 as the tractability anchor when discussing potency (pChEMBL 9.1).
Activity source · ChEMBL 36 via Core Engine
8 approved
pChEMBL 9.1
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Nuclear receptor subfamily 4 group A member 2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P43354, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
333
Total Compounds
254
Total Assays
8
Approved Drugs
IC50: 121.0, EC50: 171.0, KD: 31.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL399603
|
9.1 | EC50 | — |
|
|
No preferred name
CHEMBL399807
|
8.5 | EC50 | — |
|
|
No preferred name
CHEMBL401032
|
8.4 | EC50 | — |
|
|
No preferred name
CHEMBL399602
|
8.4 | EC50 | — |
|
|
No preferred name
CHEMBL5405485
|
8.0 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
PITAVASTATIN
CHEMBL1201753
|
2009 |
Source Header